Effects of arsenite exposure during fetal development on energy metabolism and susceptibility to diet-induced fatty liver disease in male mice

Environmental Health Perspectives

Volumn 124, Issue 2, 2016, Pages 201-209

  Ditzel, Eric J ^a   Nguyen, Thu ^a   Parker, Patricia ^a   Camenisch, Todd D ^a,b,c,d,e  

^a Sri ramakrishna institute of paramedical sciences   (India)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c Southwest Environmental Health Sciences Center   (India)

^d UNIVERSITY OF ARIZONA   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; ARSENIC TRIOXIDE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN A1C; ARSENOUS ACID DERIVATIVE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIETARY INTAKE; DISEASE PREDISPOSITION; ENERGY METABOLISM; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; FATTY LIVER; FETUS DEVELOPMENT; GENE EXPRESSION; GLUCOSE METABOLISM; HISTOPATHOLOGY; HYPERGLYCEMIA; INSULIN RESISTANCE; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; TANDEM MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL; WEANING; ADVERSE EFFECTS; ANIMAL; FEMALE; METABOLIC DISEASES; METABOLISM; PREGNANCY; PRENATAL EXPOSURE; WESTERN DIET;

ANIMALS; ARSENITES; DIET, WESTERN; DISEASE SUSCEPTIBILITY; ENERGY METABOLISM; FATTY LIVER; FEMALE; MALE; METABOLIC DISEASES; MICE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84956601509     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1409501     Document Type: Article

References (47)

1. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, et al. 2004. Increase in long-chain polyunsaturated fatty acid n–6/n–3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 106(6):635-643; doi:10.1042/CS20030326.
2. Arteel GE, Guo L, Schlierf T, Beier JI, Kaiser JP, Chen TS, et al. 2008. Subhepatotoxic exposure to arsenic enhances lipopolysaccharide-induced liver injury in mice. Toxicol Appl Pharmacol 226(2):128-139; doi:10.1016/j.taap.2007.08.020.
3. Bergquist ER, Fischer RJ, Sugden KD, Martin BD. 2009. Inhibition by methylated organo-arsenicals of the respiratory 2-oxo-acid dehydrogenases. J Organomet Chem 694(6):973-980; doi:10.1016/j.jorganchem.2008.12.028.
4. Bräuner EV, Nordsborg RB, Andersen ZJ, Tjønneland A, Loft S, Raaschou-Nielsen O. 2014. Long-term exposure to low-level arsenic in drinking water and diabetes incidence: a prospective study of the Diet, Cancer and Health cohort. Environ Health Perspect 122:1059-1065; doi:10.1289/ehp.1408198.
5. Chen Y, Ahsan H, Slavkovich V, Peltier GL, Gluskin RT, Parvez F, et al. 2010. No association between arsenic exposure from drinking water and diabetes mellitus: a cross-sectional study in Bangladesh. Environ Health Perspect 118:1299-1305; doi:10.1289/ehp.0901559.
6. Crespo J, Cayón A, Fernández-Gil P, Hernández- Guerra M, Mayorga M, Domínguez-Díez A, et al. 2001. Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34(6):1158-1163; doi:10.1053/jhep.2001.29628.
7. Dávila-Esqueda ME, Morales JM, Jiménez-Capdeville ME, De la Cruz E, Falcón-Escobedo R, Chi-Ahumada E, et al. 2011. Low-level subchronic arsenic exposure from prenatal developmental stages to adult life results in an impaired glucose homeostasis. Exp Clin Endocrinol Diabetes 119(10):613-617; doi:10.1055/s-0031-1287782.
8. Dungan KM. 2008. 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev Mol Diagn 8(1):9-19; doi:10.1586/14737159.8.1.9.
9. Ganti S, Taylor SL, Abu Aboud O, Yang J, Evans C, Osier MV, et al. 2012. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res 72(14):3471-3479; doi:10.1158/0008-5472.CAN-11-3105.
10. Grotto D, Zied E. 2010. The Standard American Diet and its relationship to the health status of Americans. Nutr Clin Pract 25(6):603-612; doi:10.1177/0884533610386234.
11. Grygiel-Górniak B. 2014. Peroxisome proliferatoractivated receptors and their ligands: nutritional and clinical implications—a review. Nutr J 13:17-2891-13-17; doi:10.1186/1475-2891-13-17.
12. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. 2001. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15(10):1667-1672; doi:10.1046/j.1365-2036.2001.01083.x.
13. Hawkesworth S, Wagatsuma Y, Kippler M, Fulford AJ, Arifeen SE, Persson LA, et al. 2013. Early exposure to toxic metals has a limited effect on blood pressure or kidney function in later childhood, rural Bangladesh. Int J Epidemiol 42(1):176-185; doi:10.1093/ije/dys215.
14. Higashi T, Maruyama E, Otani T, Sakamoto Y. 1965. Studies on the isocitrate dehydrogenase. I. Some properties of isocitrate dehydrogenase of beef heart muscle. J Biochem 57(6):793-798.
15. Hosseini MJ, Shaki F, Ghazi-Khansari M, Pourahmad J. 2013. Toxicity of arsenic (III) on isolated liver mitochondria: a new mechanistic approach. Iran J Pharm Res 12(suppl):121-138.
16. Hughes MF. 2002. Arsenic toxicity and potential mechanisms of action. Toxicol Lett 133(1):1-16; doi:10.1016/S0378-4274(02)00084-X.
17. Kirk EP, Klein S. 2009. Pathogenesis and pathophysiology of the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 11(12):761-765; doi:10.1111/j.1559-4572.2009.00054.x.
18. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. 2005. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6):1313-1321; doi:10.1002/hep.20701.
19. Kozul-Horvath CD, Zandbergen F, Jackson BP, Enelow RI, Hamilton JW. 2012. Effects of low-dose drinking water arsenic on mouse fetal and postnatal growth and development. PLoS One 7(5):e38249; doi:10.1371/journal.pone.0038249.
20. Liao YT, Chen CJ, Li WF, Hsu LI, Tsai LY, Huang YL, et al. 2012. Elevated lactate dehydrogenase activity and increased cardiovascular mortality in the arsenic-endemic areas of southwestern Taiwan. Toxicol Appl Pharmacol 262(3):232-237; doi:10.1016/j.taap.2012.04.028.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis modelassessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412-419.
22. Maull EA, Ahsan H, Edwards J, Longnecker MP, Navas-Acien A, Pi J, et al. 2012. Evaluation of the association between arsenic and diabetes: a National Toxicology Program workshop review. Environ Health Perspect 120:1658-1670; doi:10.1289/ehp.1104579.
23. Nassir F, Adewole OL, Brunt EM, Abumrad NA. 2013. CD36 deletion reduces VLDL secretion, modulates liver prostaglandins, and exacerbates hepatic steatosis in ob/ob mice. J Lipid Res 54(11):2988-2997; doi:10.1194/jlr.M037812.
24. Paschos P, Paletas K. 2009. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 13(1):9-19.
25. Paulson DJ, Ward KM, Shug AL. 1984. Malonyl CoA inhibition of carnitine palmityltransferase in rat heart mitochondria. FEBS Lett 176(2):381-384; doi:10.1016/0014-5793(84)81201-6.
26. Pettinelli P, Videla LA. 2011. Up-regulation of PPAR-γ mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab 96(5):1424-1430; doi:10.1210/jc.2010-2129.
27. Pol S, Nalpas B, Vassault A, Bousquet-Lemercier B, Franco D, Lacour B, et al. 1991. Hepatic activity and mRNA expression of aspartate aminotransferase isoenzymes in alcoholic and nonalcoholic liver disease. Hepatology 14(4 pt 1):620-625; doi:10.1002/hep.1840140408.
28. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. 2007. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46(4):1081-1090; doi:10.1002/hep.21763.
29. Reilly MP, Saca JC, Hamilton A, Solano RF, Rivera JR, Whitehouse-Innis W, et al. 2014. Prepubertal exposure to arsenic(III) suppresses circulating insulin-like growth factor-1 (IGF-1) delaying sexual maturation in female rats. Reprod Toxicol 44:41-49; doi:10.1016/j.reprotox.2013.09.005.
30. Rustin P, Bourgeron T, Parfait B, Chretien D, Munnich A, Rötig A. 1997. Inborn errors of the Krebs cycle: a group of unusual mitochondrial diseases in human. Biochim Biophys Acta 1361(2):185-197; doi:10.1016/S0925-4439(97)00035-5.
31. Sanchez-Soria P, Broka D, Quach S, Hardwick RN, Cherrington NJ, Camenisch TD. 2014. Fetal exposure to arsenic results in hyperglycemia, hypercholesterolemia, and nonalcoholic fatty liver disease in adult mice. J Toxicol Health 1(1); doi:10.7243/2056-3779-1-1.
32. Schiller CM, Fowler BA, Woods JS. 1977. Effects of arsenic on pyruvate dehydrogenase activation. Environ Health Perspect 19:205-207.
33. Shi X, Wei X, Koo I, Schmidt RH, Yin X, Kim SH, et al. 2014. Metabolomic analysis of the effects of chronic arsenic exposure in a mouse model of diet-induced fatty liver disease. J Proteome Res 13(2):547-554; doi:10.1021/pr400719u.
34. Simonen P, Kotronen A, Hallikainen M, Sevastianova K, Makkonen J, Hakkarainen A, et al. 2011. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol 54(1):153-159; doi:10.1016/j.jhep.2010.05.037.
35. Smedley PL, Kinniburgh DG. 2002. A review of the source, behaviour and distribution of arsenic in natural waters. Appl Geochem 17(5):517-568; doi:10.1016/S0883-2927(02)00018-5.
36. Sookoian S, Castaño GO, Burgueño AL, Rosselli MS, Gianotti TF, Mallardi P, et al. 2010. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 209(2):585-591; doi:10.1016/j.atherosclerosis.2009.10.011.
37. Srivastava S, D’Souza SE, Sen U, States JC. 2007. In utero arsenic exposure induces early onset of atherosclerosis in ApoE-/- mice. Reprod Toxicol 23(3):449-456; doi:10.1016/j.reprotox.2007.01.005.
38. States JC, Singh AV, Knudsen TB, Rouchka EC, Ngalame NO, Arteel GE, et al. 2012. Prenatal arsenic exposure alters gene expression in the adult liver to a proinflammatory state contributing to accelerated atherosclerosis. PLoS One 7(6):e38713; doi:10.1371/journal.pone.0038713.
39. Su CT, Lin HC, Choy CS, Huang YK, Huang SR, Hsueh YM. 2012. The relationship between obesity, insulin and arsenic methylation capability in Taiwan adolescents. Sci Total Environ 414:152-158; doi:10.1016/j.scitotenv.2011.10.023.
40. Tan M, Schmidt RH, Beier JI, Watson WH, Zhong H, States JC, et al. 2011. Chronic subhepatotoxic exposure to arsenic enhances hepatic injury caused by high fat diet in mice. Toxicol Appl Pharmacol 257(3):356-364; doi:10.1016/j.taap.2011.09.019.
41. Wauson EM, Langan AS, Vorce RL. 2002. Sodium arsenite inhibits and reverses expression of adipogenic and fat cell-specific genes during in vitro adipogenesis. Toxicol Sci 65(2):211-219.
42. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. 2008. Increased hepatic and circulatinginterleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 103(6):1372-1379; doi:10.1111/j.1572-0241.2007.01774.x.
43. Yoshida T, Yamauchi H, Fan Sun G. 2004. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol Appl Pharmacol 198(3):243-252; doi:10.1016/j.taap.2003.10.022.
44. Yoshikawa T, Shimano H, Yahagi N, Ide T, Amemiya- Kudo M, Matsuzaka T, et al. 2002. Polyunsaturated fatty acids suppress sterol regulatory elementbinding protein 1c promoter activity by inhibition of liver X receptor (LXR) binding to LXR response elements. J Biol Chem 277(3):1705-1711; doi:10.1074/jbc.M105711200.
45. Yuan Y, Marshall G, Ferreccio C, Steinmaus C, Selvin S, Liaw J, et al. 2007. Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed region II of Chile from 1950 to 2000. Am J Epidemiol 166(12):1381-1391; doi:10.1093/aje/kwm238.
46. Zhang J, Zhao Y, Xu C, Hong Y, Lu H, Wu J, et al. 2014. Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Sci Rep 4:5832; doi:10.1038/srep05832.
47. Zhao F, Severson P, Pacheco S, Futscher BW, Klimecki WT. 2013. Arsenic exposure induces the Warburg effect in cultured human cells. Toxicol Appl Pharmacol 271(1):72-77; doi:10.1016/j.taap.2013.04.020.